The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-01), Challenger's 9-Day RSI is 78.79.
The industry rank for Challenger's 9-Day RSI or its related term are showing as below:
ASX:CGF's 9-Day RSI is ranked worse than 81.14% of 594
companies
in the Insurance industry
Industry Median: 54.865
vs ASX:CGF: 78.79
Challenger (ASX:CGF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Challenger 9-Day RSI Related Terms
ASX:CGF vs AFL, MET, PRU: 9-Day RSI Comparison
For the Insurance - Life subindustry, Challenger's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Challenger 9-Day RSI vs Insurance Industry
For the Insurance industry and Financial Services sector, Challenger's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Challenger's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Challenger (ASX:CGF) has a 9-Day RSI of 78.79 as of Jul. 01, 2026. According to the industry distribution chart, Challenger ranks #482 out of 594 companies in the Insurance industry, placing it in the top 81.1%.
Is Challenger's 9-Day RSI too high?
Challenger's current 9-Day RSI is 78.79. The Insurance industry median 9-Day RSI is 54.87. Challenger's value of 78.79 is 43.6% above this industry median. Based on the distribution chart, Challenger ranks #482 out of 594 companies in the Insurance industry, which is in the bottom quartile relative to peers. Overall, Challenger has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Challenger's 9-Day RSI compare to AFL and MET?
According to the Insurance industry distribution chart, Challenger ranks #482 out of 594 companies for 9-Day RSI. This places Challenger in the lower half of its industry. The industry median 9-Day RSI is 54.87. Challenger's value of 78.79 is 43.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for an Insurance company?
The median 9-Day RSI among Insurance companies is 54.87, based on 594 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Challenger's current 9-Day RSI of 78.79 is 43.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Insurance industry, the median 9-Day RSI is 54.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Challenger's current 9-Day RSI is 78.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Challenger stock overvalued right now?
Based on GuruFocus' analysis, Challenger (ASX:CGF) is currently considered Significantly Overvalued. The stock's GF Value™ is A$4.00, compared to a current price of A$10.26 — trading 156.5% above its estimated fair value. The current 9-Day RSI is 78.79 and 43.6% above the Insurance industry median of 54.87. Challenger's overall GF Score™ is 58/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Challenger (ASX:CGF), the current 9-Day RSI is 78.79 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Challenger (ASX:CGF) Overvalued in 2026?
Based on GuruFocus' analysis, Challenger stock appears to be overvalued.
The current stock price of A$10.26 is trading 156.5% above its estimated GF Value™ of A$4.00.
GuruFocus considers Challenger to be Significantly Overvalued.
Key valuation signals for ASX:CGF:
9-Day RSI: 78.79
GF Value™: A$4.00 vs. price of A$10.26 (156.5% above fair value)
Industry Position: 43.6% above the Insurance median (#482 of 594)
No single metric tells the full story. See the ASX:CGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Challenger's core business is selling annuity products in the Australian retirement market and, since November 2016, selling Australian dollar-denominated annuities into Japan's large retirement market. The firm's annuity products provide investors guaranteed regular payments over an agreed term for an upfront lump sum investment and is designed primarily to protect investors from the longevity risk of outliving their savings. Challenger also operates a funds management business, Fidante Partners, which has minority stakes in several boutique global investment managers, and Challenger Investment Management, which primarily manages investments supporting its annuities business.
58GF Score
Get the complete analysis for ASX:CGF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGF has been successfully added to your 